Calidi Biotherapeutics reported its fourth quarter and full-year 2025 financial results, including a net loss of $4.1 million for Q4 2025 and $25.6 million for the full year. The company also announced recent operational developments, including partnerships to advance its lead asset CLD-401 and a capital raise of $6.5 million.
Key takeaways
Reported Q4 2025 net loss attributable to common stockholders of $4.1 million, or $0.57 per share, compared to $4.1 million, or $3.23 per share, in Q4 2024.
Reported full-year 2025 net loss attributable to common stockholders of $25.6 million, or $5.95 per share, compared to $23.8 million, or $35.70 per share, in 2024.
Raised $6.5 million in gross proceeds from a public offering and ATM sales in Q1 2026 and Q4 2025, respectively.
Partnered with Avance Clinical to accelerate initiation of a first-in-human clinical trial for lead asset CLD-401 in Australia.
Partnered with Matica Bio for GMP manufacturing of CLD-401.
Expects to file an IND for CLD-401 with the FDA by the end of 2026.